RT Journal
A1 Voelker R
T1 MDr-tb has new drug foe after fast-track approval
JF JAMA
JO JAMA
YR 2013
FD February 6
VO 309
IS 5
SP 430
OP 430
DO 10.1001/jama.2013.94
UL http://dx.doi.org/10.1001/jama.2013.94
AB 
MDR-TB “poses a serious health threat throughout the world, and [bedaquiline] provides much-needed treatment for patients who don't have other therapeutic options,” said Edward Cox, MD, MPH, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research, in a statement.